ContractExclusive License and Sponsored Research Agreement • May 5th, 2020 • Delaware
EX-10.31 7 v52057a5exv10w31.htm EX-10.31 Exhibit 10.31 EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and MEDICAL RESEARCH COUNCIL This license agreement (the “Agreement”) is made effective the 31st day of October 2005 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Medical Research Council, a United Kingdom governmental institution having a place of business at 20 Park Crescent, London, United Kingdom, W1B 1AL (“MRC”). WHEREAS MRC owns rights to certain technology related to mannan-binding lectin associated serine protease-2 (“MASP-2”), which technology was developed in part by Anthony C. Willis (“Mr. Willis”) working in an MRC laboratory under the direction of Professor Kenneth B. M. Reid (“Dr. Reid”), both employees of MRC; WHEREAS Omeros holds an exclusive, worldwide license to rights owned by the University of Leicest
ContractExclusive License and Sponsored Research Agreement • May 5th, 2020 • Delaware
EX-10.29 6 v52057a5exv10w29.htm EX-10.29 Exhibit 10.29 EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT between OMEROS CORPORATION and the UNIVERSITY OF LEICESTER This license agreement (the “Agreement”) is made effective the 10th day of June 2004 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and the University of Leicester, having a principal place of business at University Road, Leicester LE1 7RH, United Kingdom (“Leicester”). WHEREAS Leicester owns rights to certain technology related to mannan-binding lectin associated serine protease-2 (“MASP-2”) and a MASP-2 related plasma protein of 19 kDa commonly referred to as “MAp19”, which technology was developed in whole or in part by Wilhelm J. Schwaeble, Ph.D., (“Dr. Schwaeble” or the “Principal Investigator”) and Cordula M. Stover, Ph.D. (“Dr. Stover”), both employees of Leicester, and has obtained owne
AMENDMENT dated 8 May 2007 of the EXCLUSIVE LICENSE AND SPONSORED RESEARCH AGREEMENT dated 31 October 2005 By and between MEDICAL RESEARCH COUNCIL and OMEROS CORPORATIONExclusive License and Sponsored Research Agreement • January 9th, 2008 • Omeros Corp
This is an amendment (this “Amendment”) effective 8 May 2007 of the Exclusive License and Sponsored Research Agreement between Medical Research Council (“MRC”) and Omeros Corporation (“Omeros”) dated 31 October 2005 (“the Agreement”). All initial capitalized terms used herein below shall have the same definition as set forth in the Agreement.
